vTv Therapeutics Inc. (VTVT): Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026
vTv Therapeutics Inc. (VTVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid
How this was made
The 30-second read
Why it matters
The 8-K updates financials and reiterates a development roadmap: Phase 3 CATT1 enrollment completion expected in Q3 2026, Phase 2a Hybrid CATT1 initiation before year-end 2026, and a Q4 2026 KOL event. It also states the current cash position should fund operations through the anticipated CATT1 topline data readout.
Market read
Traders can use the updated cash runway and trial schedule to adjust near-to-mid-term risk pricing into the next major milestone (Q3 2026 enrollment completion) and the later topline readout window.
What to watch
The filing does not provide new efficacy/safety data for cadisegliatin, so the main tradable element is schedule visibility rather than clinical outcome confirmation.
Background
vTv Therapeutics is advancing cadisegliatin (TTP399), an oral glucokinase activator, in a Phase 3 trial (CATT1) for type 1 diabetes as an adjunct to insulin.
Ticker impact
vTv reports Q2 2026 results and expects Phase 3 CATT1 enrollment completion in Q3 2026, with cash funding through the topline readout.
Near-term bias to the upside on improved visibility into enrollment completion and funding duration, with volatility into subsequent trial milestones.
The article is a primary SEC 8-K with specific forward-looking milestones (enrollment completion in Q3 2026, Phase 2a initiation before year-end 2026) and a quantified cash position ($86.6M at June 30, 2026) tied to funding through topline.
Market effects
Adds incremental sentiment to oral adjunctive therapy narratives in T1D, but impact is company-specific rather than sector-wide.
Limited, as the disclosure is US-listed and not tied to a broader regional macro or policy event.
Low, since the update is focused on US clinical development timelines and company finances.
Counterpoint
Cash runway and enrollment timing may not translate into topline success; investors may discount the update if prior trial endpoints have been challenging in T1D.
Key entities
- companyvTv Therapeutics Inc.
Nasdaq-listed biopharmaceutical company reporting Q2 2026 financial results and clinical program updates for cadisegliatin.
- drug_programCadisegliatin (TTP399)
Oral investigational therapy for type 1 diabetes, evaluated in Phase 3 CATT1 and Phase 2a Hybrid CATT1.
- clinical_trialPhase 3 CATT1 trial
Evaluates cadisegliatin as an oral adjunct to insulin in T1D; enrollment completion expected in Q3 2026.